Answers are grounded in this paper and cite their sources.
Nasopharyngeal Carcinoma (NPC) is a major public health problem in endemic zones. NPC is correlated with substantial illness and death; thus, superior treatment is desired. Rosmanol (RM) is a phenolic diterpene antioxidant extracted from the medicinal herb Rosemary (Rosmarinus officinalis). RM has been investigated for its anti-inflammatory and anti-tumor properties by numerous signaling cascades. However, the fundamental anticancer latent mechanism of RM persists as unidentified. Hence, this present research proposes to search for the anti-cancer efficacy of RM on human NPC cells CNE2 using an in vitro approach. To assess the possible molecular mechanisms of proliferation, apoptosis, cell-cycle regulatory proteins, and MAPKs/NF-κB signaling of NPC cells were administered RM (20 and 30 µM) and assayed through MTT, DCFH-DA, Rh-123 staining, AO/EB, PI, Rh-123/DAPI merge form staining, RT-PCR, and Western blot. The result was recognized that RM could reduce NPC cell viability by elevated intracellular ROS, MMP damage, and generate apoptosis. RM inhibits the Cyclin-D1, Bax, TNF-α, and NF-κB, and induces BCl-2 analyzed via RT PCR. RM attenuates the cell cycle mechanism by repressing NPC cell cycle-related proteins: CDK4/CDK6, pRB, cyclin-D1, and MAPKs/NF-κB signaling. These data established that the MAPKs/NF-κB pathway is a potential target for the remedial action of RM. In summary, RM may be an effective conventional chemotherapy drug in preventing the progression of NPC.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: